1
|
Dol C, Granel B, Resseguier N, Kaplanski G, Reynaud-Gaubert M, Schleinitz N, Grob JJ, Delaporte E, Lafforgue P, Rossi P, Bardin N, Benyamine A. [High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis]. Rev Med Interne 2024; 45:126-131. [PMID: 38355359 DOI: 10.1016/j.revmed.2023.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 10/29/2023] [Accepted: 11/04/2023] [Indexed: 02/16/2024]
Abstract
BACKGROUND Anti-centromere antibodies, anti-topoisomerase-1 antibodies (ATA), and anti-RNA-polymerase III antibodies are three Systemic Sclerosis (SSc)-specific autoantibodies. Their detection is helpful in determining the prognosis. We aimed to evaluate whether ATA levels were associated with disease severity at diagnosis or disease progression during follow-up in ATA positive patients. METHODS We conducted a single-centre French retrospective observational study, between 2014 and 2021. ATA positive patients fulfilling the ACR/EULAR 2013 classification criteria for SSc with a minimal follow-up of 1 year and 2 ATA dosages were included. SSc patients with high IgG ATA levels at baseline (>240IU/mL) were compared with SSc patients with low levels (≤240IU/mL), at inclusion and at 1 and 3 years. A variation of at least 30 % of ATA levels was considered significant. RESULTS Fifty-nine SSc patients were included and analysed. There was a predominance of women and of patients with diffuse interstitial lung disease. Patients with high ATA levels exhibited a higher skin sclerosis assessed by the modified Rodnan skin score (P=0.0480). They had a lower carbon monoxide transfer coefficient (P=0.0457), a lower forced vital capacity (FVC) (P=0.0427) and more frequently had a FVC under 80 %, when compared to patients with low ATA levels (P=0.0423). Initial high ATA levels were associated with vascular progression at one year (21.95 % vs. 0 %; P=0.0495). CONCLUSION ATA levels are associated with skin sclerosis and vascular progression in SSc. Beyond the detection of ATA, quantifying this autoantibody might be of interest in predicting disease severity and prognosis in SSc.
Collapse
Affiliation(s)
- C Dol
- Service de médecine interne, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), chemin des Bourrely, 13015 Marseille, France
| | - B Granel
- Service de médecine interne, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), chemin des Bourrely, 13015 Marseille, France; Inserm, INRA, C2VN, Aix-Marseille université (AMU), 13005 Marseille, France
| | - N Resseguier
- Épidémiologie et économie de la santé, hôpital de la Timone, AP-HM, Aix-Marseille université (AMU), 13005 Marseille, France
| | - G Kaplanski
- Inserm, INRA, C2VN, Aix-Marseille université (AMU), 13005 Marseille, France; Service de médecine interne et immunologie clinique, hôpital de la Conception, Assistance publique des Hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - M Reynaud-Gaubert
- Service de pneumologie, équipe de transplantation pulmonaire, centre de compétences des maladies pulmonaires rares, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), Aix-Marseille université (AMU), 13015 Marseille, France
| | - N Schleinitz
- Service de médecine interne, hôpital de la Timone, Assistance publique des Hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - J-J Grob
- Service de dermatologie, hôpital de la Timone, Assistance publique des Hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - E Delaporte
- Service de dermatologie, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), 13015 Marseille, France
| | - P Lafforgue
- Service de rhumatologie, hôpital Sainte-Marguerite, Assistance publique des Hôpitaux de Marseille (AP-HM), 13009 Marseille, France
| | - P Rossi
- Service de médecine interne, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), chemin des Bourrely, 13015 Marseille, France; Inserm, INRA, C2VN, Aix-Marseille université (AMU), 13005 Marseille, France
| | - N Bardin
- Inserm, INRA, C2VN, Aix-Marseille université (AMU), 13005 Marseille, France; Laboratoire d'immunologie, biogénopole, hôpital de la Timone, Assistance publique des Hôpitaux de Marseille (AP-HM), 13005 Marseille, France
| | - A Benyamine
- Service de médecine interne, hôpital Nord, Marseille, Assistance publique des Hôpitaux de Marseille (AP-HM), chemin des Bourrely, 13015 Marseille, France; Inserm, INRA, C2VN, Aix-Marseille université (AMU), 13005 Marseille, France.
| |
Collapse
|